Media stories about Amyris (NASDAQ:AMRS) have trended positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amyris earned a news sentiment score of 0.29 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.2839637283381 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Head to Head Analysis: Amyris (AMRS) and Its Peers (americanbankingnews.com)
- Amyris, Inc. (AMRS) Stock Charts Regains Attentions on Financial Ratio Analysis (investingbizz.com)
- Trend Analysis – Amyris Inc (NASDAQ: AMRS) (stockspen.com)
- Amyris (AMRS) Cut to “Hold” at ValuEngine (americanbankingnews.com)
- Amyris, Inc. (NASDAQ:AMRS) – Hot Mover of the Day (nasdaqjournal.com)
A number of research firms have recently weighed in on AMRS. ValuEngine downgraded shares of Amyris from a “buy” rating to a “hold” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Amyris in a report on Monday. B. Riley set a $10.00 price objective on shares of Amyris and gave the stock a “buy” rating in a report on Tuesday, March 20th. Finally, Zacks Investment Research upgraded shares of Amyris from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.19.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.24). The company had revenue of $80.59 million for the quarter, compared to analysts’ expectations of $68.14 million. The company’s quarterly revenue was up 262.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) EPS. sell-side analysts forecast that Amyris will post -0.59 earnings per share for the current fiscal year.
In other Amyris news, insider John Melo sold 10,776 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total transaction of $50,431.68. Following the completion of the sale, the insider now directly owns 83,172 shares in the company, valued at $389,244.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.30% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Amyris (NASDAQ:AMRS) Receives Daily News Sentiment Score of 0.29” was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://baseballnewssource.com/2018/04/05/amyris-amrs-earns-daily-coverage-optimism-rating-of-0-29/2028989.html.
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.